Welcome to LookChem.com Sign In|Join Free
  • or
N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol is a complex chemical compound characterized by the presence of a Boc-protected amine group (N-Boc) and a hydroxyl group. It is derived from the bicyclic compound 3-oxa-7-azabicyclo[3.3.1]nonane, which contributes to its unique molecular structure. N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol may hold potential for various applications in organic synthesis, medicinal chemistry, and drug development due to its distinctive structural features and functional groups. Careful handling, proper safety protocols, and adherence to storage and disposal procedures are essential when working with N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol.

228270-33-5

Post Buying Request

228270-33-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

228270-33-5 Usage

Uses

Used in Organic Synthesis:
N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structure and functional groups facilitate the formation of new chemical bonds and the synthesis of target compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol is utilized as a building block for the development of novel pharmaceutical agents. Its Boc-protected amine group and hydroxyl group can be further modified to create bioactive molecules with potential therapeutic applications.
Used in Drug Development:
N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol is employed as a precursor in drug development for the synthesis of new drug candidates. Its unique molecular structure and functional groups can be exploited to design and optimize compounds with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Pharmaceutical Industry:
N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol is used as a chemical intermediate in the pharmaceutical industry for the synthesis of active pharmaceutical ingredients (APIs). Its unique structure and functional groups enable the development of innovative drugs with improved therapeutic profiles.
Used in Research and Development:
In research and development, N-Boc-3-oxa-7-azabicyclo[3.3.1]nonan-9-ol serves as a valuable tool for studying the synthesis and properties of complex organic molecules. Its unique structure and functional groups provide insights into the reactivity and selectivity of various chemical reactions, contributing to the advancement of synthetic methodologies and the discovery of new chemical entities.

Check Digit Verification of cas no

The CAS Registry Mumber 228270-33-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,8,2,7 and 0 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 228270-33:
(8*2)+(7*2)+(6*8)+(5*2)+(4*7)+(3*0)+(2*3)+(1*3)=125
125 % 10 = 5
So 228270-33-5 is a valid CAS Registry Number.

228270-33-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl (1R,5S,9r)-9-hydroxy-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:228270-33-5 SDS

228270-33-5Relevant academic research and scientific papers

FXR receptor agonist

-

, (2019/02/10)

The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.

PYRIMIDINE ETHER DERIVATIVES AND METHODS OF USE THEREOF

-

Page/Page column 32, (2011/06/19)

The present invention relates to Pyrimidine Ether Derivatives, compositions comprising a Pyrimidine Ether Derivative, and methods of using the Pyrimidine Ether Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 228270-33-5